MD Stem Cells

MD Stem Cells and Stem Cell Treatments

MD Stem Cellsis aconsultancy providing information, education, facilitationand access to advanced Stem Cell and Alternative Medicine treatments in the United States and Europe. We are now Collaborator and Study Director for the Stem Cell Ophthalmology Treatment Study- SCOTS - the largest and most comprehensive stem cell eye study registered with the National Institutes of Health. Please see the NIH website http://www.clinicaltrials.gov Identifier NCT 01920867. SCOTS is now recruiting and accepting patients.

Conditions eligible for the SCOTS trial include retinal diseases such as age-related macular degeneration (AMD), myopic macular degeneration, hereditary retinopathies such as Retinitis Pigmentosa and Stargardts, as well as selected inflammatory, vascular and traumatic conditions. Optic nerve diseases considered eligible include glaucoma, ischemic optic neuropathy, optic atrophy, optic neuritis and some trauma. The study is focused on the ocular tissue that has sustained damage and its potential for improvement rather than a specific disease entity.

MD Stem Cells and its staff do not provide medical evaluation, diagnosis, advice or treatment but rather act to connect interested patients with leading physicians and centers of excellence. We encourage you to carefully review the material presented and, should you have interest, complete the Contact Us form and we will be in touch shortly.

Disclaimer: The Stem Cell Ophthalmology Treatment Study or SCOTS is an open label, non-randomized efficacy study and no guarantees of specific improvements or visual results are being made. Any medical procedure carries risks as well as potential benefits. The SCOTS study has different treatment arms and our principle investigator assigns patients to minimize risk and maximize potential benefit. Depending on the arm chosen the risk of potential complications has been calculated to be from approximately 0.0008% to 5%.

Disclaimer: The Stem Cell Ophthalmology Treatment Study or SCOTS is an open label, non-randomized efficacy study and no guarantees of specific improvements or visual results are being made. Any medical procedure carries risks as well as potential benefits. The SCOTS study has different treatment arms and our principle investigator assigns patients to minimize risk and maximal potential benefit. Depending on the arm chosen the risk of potential complications has been calculated to be from approximately 0.0008% to 5%. - See more at: http://www.mdstemcells.com/SCOTSQuestionsonstemcells.html#sthash.VO6wDC9d.dpuf

Disclaimer: The Stem Cell Ophthalmology Treatment Study or SCOTS is an open label, non-randomized efficacy study and no guarantees of specific improvements or visual results are being made. Any medical procedure carries risks as well as potential benefits. The SCOTS study has different treatment arms and our principle investigator assigns patients to minimize risk and maximal potential benefit. Depending on the arm chosen the risk of potential complications has been calculated to be from approximately 0.0008% to 5%. - See more at: http://www.mdstemcells.com/SCOTSQuestionsonstemcells.html#sthash.VO6wDC9d.dpu

MD Stem Cells 412 Main Street, Suite I Ridgefield, CT 06877 USA Tel:203-423-9494 Fax: 203-905-6800 Email: info@mdstemcells.com

Read more from the original source:
MD Stem Cells